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Abstract A major constraint on the evolution of large body sizes in animals is an increased risk
of developing cancer. There is no correlation, however, between body size and cancer risk. This
lack of correlation is often referred to as ’Peto’s Paradox’. Here, we show that the elephant
genome encodes 20 copies of the tumor suppressor gene TP53 and that the increase in TP53 copy
number occurred coincident with the evolution of large body sizes, the evolution of extreme
sensitivity to genotoxic stress, and a hyperactive TP53 signaling pathway in the elephant
(Proboscidean) lineage. Furthermore, we show that several of the TP53 retrogenes (TP53RTGs) are
transcribed and likely translated. While TP53RTGs do not appear to directly function as
transcription factors, they do contribute to the enhanced sensitivity of elephant cells to DNA
damage and the induction of apoptosis by regulating activity of the TP53 signaling pathway. These
results suggest that an increase in the copy number of TP53 may have played a direct role in the
evolution of very large body sizes and the resolution of Peto’s paradox in Proboscideans.
DOI: 10.7554/eLife.11994.001
Introduction
Lifespan and maximum adult body size are fundamental life history traits that vary considerably
between species (Healy et al., 2014). The maximum lifespan among vertebrates, for example,
ranges from over 211 years in the bowhead whale (Balaena mysticetus) to only 59 days in the pygmy
goby (Eviota sigillata) whereas body sizes ranges from 136,000 kg in the blue whale (Balaenoptera
musculus) to 0.5 g in the Eastern red-backed salamander (Plethodon cinereus) (Healy et al., 2014).
Similar to other life history traits, such as body size and metabolic rate or body size and age at matu-
ration, body size and lifespan are strongly correlated such that larger species tend to live longer
than smaller species (Figure 1A). While abiotic and biological factors have been proposed as major
drivers of maximum body size evolution in animals, maximum body size within tetrapods appears to
be largely determined by biology (Smith et al., 2010; Sookias et al., 2012). Mammals, for example,
likely share biological constraints on the evolution of very large body sizes with rare breaks in those
constraints underlying the evolution of gigantism in some lineages (Sookias et al., 2012), such as
Proboscideans (elephants and their and extinct relatives), Cetaceans (whales), and the extinct horn-
less rhinoceros Paraceratherium (‘Walter’).
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eLife digest As time passes, healthy cells are more likely to become cancerous because more
and more damaging mutations accumulate in the cell’s DNA. Assuming that all cells have a similar
risk of acquiring mutations, larger and longer-lived animals – like elephants – should have a higher
risk of cancer than smaller, shorter-lived animals – like mice. However, there does not appear to be
any link between the size of an animal and its risk of developing cancer. Consequently, a key
question in cancer biology is how very large animals protect themselves against these diseases.
One gene that is often damaged during an animal’s lifetime is called TP53. This gene normally
produces a tumor suppressor protein that senses when DNA is damaged or a cell is under stress and
either briefly slows the cell’s growth while the damage is repaired or triggers cell death if the stress
is overwhelming. One way that large animals could reduce their risk of cancer is to have extra copies
of TP53 or other genes that encode tumor suppressor proteins.
Here Sulak et al. used an evolutionary genomics approach to study TP53 in 61 animals of various
sizes, including several large animals such as African elephants and Minke whales. All of the animals
studied had at least one copy of TP53, and several had a few extra copies, known as TP53
retrogenes. African elephants – the largest living land mammal – had more retrogenes than any of
the others with 19 in total. To investigate why African elephants have so many TP53 retrogenes,
Sulak et al. also analyzed DNA from Asian elephants and several other closely related, but now
extinct species, including the woolly mammoth. As expected, as species evolved larger body sizes
they also evolved more TP53 retrogenes.
Further experiments indicate that several of the TP53 retrogenes in African elephants are likely to
be able to produce the tumor suppressor protein and that they contribute to elephant cells being
better equipped to deal with DNA damage. The next step following on from this work will be to find
out exactly how TP53 retrogenes help to protect animals from cancer.
DOI: 10.7554/eLife.11994.002
Figure 1. Body size evolution in vertebrates. (A) Relationship between body mass (g) and lifespan (years) among 2556 vertebrates. Blue line shows the
linear regression between log (body mass) and log (lifespan), R2 = 0.32. (B) Body size comparison between living (African and Asian elephants) and
extinct (Steppe mammoth) Proboscideans, Cetaceans (Minke whale), and the extinct hornless rhinoceros Paraceratherium (‘Walter’), and humans.
DOI: 10.7554/eLife.11994.003
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A major constraint on the evolution of large body sizes in animals is an increased risk of develop-
ing cancer. If all cells have a similar risk of malignant transformation and equivalent cancer suppres-
sion mechanisms, organism with many cells should have a higher risk of developing cancer than
organisms with fewer cells; Similarly organisms with long lifespans have more time to accumulate
cancer-causing mutations than organisms with shorter lifespans and therefore should be at an
increased risk of developing cancer, a risk that is compounded in large bodied, long-lived organisms
(Cairns, 1975; Caulin and Maley, 2011; Doll, 1971; Peto, 2015; Peto et al., 1975). There are no
correlations, however, between body size and cancer risk or lifespan and cancer risk across species
(Leroi et al., 2003), this lack of correlation is often referred to as ‘Peto’s Paradox’ (Caulin and
Maley, 2011; Peto et al., 1975). Epidemiological studies in wild populations of Swedish roe deer
(Capreolus capreolus) and beluga whales (Delphinapterus leucas) in the highly polluted St. Lawrence
estuary, for example, found cancer accounted for only 2% (Aguirre et al., 1999) and 27%
(Martineau et al., 2002) of mortality, respectively, much lower than expected given body size of
these species (Caulin and Maley, 2011).
Among the mechanisms large, long lived animals may have evolved that resolve Peto’s paradox
are a decrease in the copy number of oncogenes, an increase in the copy number of tumor suppres-
sor genes (Caulin and Maley, 2011; Leroi et al., 2003; Nunney, 1999), reduced metabolic rates
leading to decreased free radical production, reduced retroviral activity and load
(Katzourakis et al., 2014), increased immune surveillance, and selection for ’cheater’ tumors that
parasitize the growth of other tumors (Nagy et al., 2007), among many others. Naked mole rats
(Heterocephalus glaber), for example, which have very long lifespans for a small-bodied organism
evolved cells with extremely sensitive contact inhibition likely acting as a constraint on tumor growth
and metastasis (Seluanov et al., 2009; Tian et al., 2013). Similarly long-lived blind mole rats (Splanx
sp.) evolved an enhanced TP53-signaling and necrotic cell death mechanisms that also likely con-
strains tumor growth (Ashur-Fabian et al., 2004; Avivi et al., 2007; Avivi et al., 2005;
Gorbunova et al., 2012; Manov et al., 2013). Thus, while some of the mechanisms that underlie
cancer resistance in small, long-lived mammals have been identified, the mechanisms by which large
bodied animals evolved enhanced cancer resistance are unknown.
Here we use evolutionary genomics and comparative cell biology to explore the mechanisms by
which elephants, the largest extant land mammal (Figure 1B), have evolved enhanced resistance to
cancer. We found that the elephant genome encodes a single TP53 gene and 19 TP53 retrogenes,
several of which are transcribed and translated in elephant tissues. Comparison of the African and
Asian elephant TP53 gene copy number with the copy number in the genome of the extinct Ameri-
can mastodon, woolly mammoth, and Columbian mammoth indicates that copy number increased
relatively rapidly coincident with the evolution of large body-sizes in the Proboscidean lineage.
Finally, we show that elephant cells have an enhanced response to DNA-damage that is mediated
by a hyperactive TP53 signaling pathway and that this augmented TP53 signaling is dependent upon
TP53 retrogenes and can be transferred to the cells of other species through exogenous expression
of elephant TP53 retrogenes. These results suggest that the origin of large body sizes, long life-
spans, and enhanced cancer resistance in the elephant lineage evolved at least in part through rein-
forcing the anti-cancer mechanisms of the major ‘guardian of the genome’ TP53.
Results
Expansion of the TP53 repertoire in proboscideans
We characterized TP53 copy number in 61 Sarcopterygians (Lobe-finned fishes) with draft or com-
pleted genomes, including large, long-lived mammals such as the African elephant (Loxodonta afri-
cana), Bowhead (Balaena mysticetus) and Minke (Balaenoptera acutorostrata scammoni) whales. We
found that all Sarcopterygian genomes encoded a single TP53 gene and that some lineages also
contained a few TP53 retrogenes (TP53RTG), including marsupials, Yangochiropteran bats, and
Glires, in which ‘processed’ TP53 pseudogenes have previously been reported (Ciotta et al., 1995;
Czosnek et al., 1984; Hulla, 1992; Tanooka et al., 1995; Weghorst et al., 1995; Zakut-
Houri et al., 1983). We also identified a single TP53RTG gene in the lesser hedgehog tenrec (Echi-
nops telfairi), which had been previously reported (Belyi et al., 2010), rock hyrax (Procavia capensis),
Sulak et al. eLife 2016;5:e11994. DOI: 10.7554/eLife.11994 3 of 30
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and West Indian manatee (Trichechus manatus). The African elephant genome, however, encoded
19 TP53RTG genes (Figure 2A), 14 of which retain potential to encode truncated proteins (Table 1).
To trace the expansion of TP53RTG gene family in the Proboscidean lineage with greater phylo-
genetic resolution, we used three methods to estimate the minimum (1:1 orthology), average (nor-
malized read depth), and maximum (gene tree reconciliation) TP53/TP53RTG copy number in the
Asian elephant (Elephas maximus), extinct woolly (Mammuthus primigenius) and Columbian (Mam-
muthus columbi) mammoths, and the extinct American mastodon (Mammut americanum) using
Figure 2. Expansion of the TP53RTG gene repertoire in Proboscideans. (A) TP53 copy number in 61 Sarcopterygian (Lobe-finned fish) genomes. Clade
names are shown for lineages in which the genome encodes more than one TP53 gene or pseudogene. (B) Estimated TP53/TP53RTG copy number
inferred from complete genome sequencing data (WGS, purple), 1:1 orthology (green), gene tree reconciliation (blue), and normalized read depth from
genome sequencing data (red). Whiskers on normalized read depth copy number estimates show the 95% confidence interval of the estimate.
DOI: 10.7554/eLife.11994.004
The following figure supplement is available for figure 2:
Figure supplement 1. Reconciled TP53/TP53RTG gene trees.
DOI: 10.7554/eLife.11994.005
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existing whole genome sequencing data (Enk et al., 2014, 2013; Rohland et al., 2010;
Wilkie et al., 2013). As expected, we identified a single canonical TP53 gene in these species and
estimated the TP53RTG copy number in the Asian elephant genome to be 12–17, approximately 14
in both the Columbian and woolly mammoth genomes, and 3–8 in the 50,000–130,000 year old
American mastodon genome (Figure 2Band Figure 2—figure supplement 1). These data indicate
that large-scale expansion of the TP53RTG gene family occurred in the Proboscidean lineage and
suggest that TP53RTG copy number was lower in ancient Proboscideans such as the mastodon,
which diverged from the elephant lineage ~ 25 MYA (Rohland et al., 2010), than in recent species
such as elephants and mammoths.
The TP53RTG repertoire expanded through repeated segmental
duplications
Several mechanisms may have increased the TP53RTG copy number in the Proboscidean lineage
including serial retrotransposition from the TP53 gene, serial retrotransposition from the TP53 and
one or more daughter transcribed retrogenes, repeated segmental duplications of chromosomal loci
containing TP53RTG genes, or some combination of these mechanisms. Consistent with copy num-
ber expansion through a single retrotransposition event followed by repeated rounds of segmental
duplication, we found that each TP53RTG retrogene was flanked by nearly identical clusters of trans-
posable elements (Figure 3A) and embedded within a large genomic region with greater than 80%
sequence similarity (Figure 3B). Next we used progressiveMAUVE to align the 18 elephant contigs
containing TP53RTG retrogenes and found that they were all embedded within large locally collinear
blocks that span nearly the entire length of some contigs (Figure 3C), as expected for segmental
duplications.
Table 1. Summary information for African elephant TP53/TP53RTG genes.
Gene Id ENSEMBL Id Scaffold (loxAfr3)
Chromosome
(loxAfr4) Coding potential ORF size
TP53 ENSLAFG00000007483 47 Chr 11 Yes 392aa
TP53RTG1 ENSLAFG00000025553 175 Unmapped No N/A
TP53RTG2 N/A 217 Unmapped Yes 134aa
TP53RTG3 ENSLAFG00000027474 406 Unmapped Yes 79aa
TP53RTG4 N/A 627 Unmapped Yes 134aa
TP53RTG5 ENSLAFG00000027348 221 Unmapped Yes 162aa
TP53RTG6 N/A 76 Chr 27 Yes 123aa
TP53RTG7 N/A 208 Unmapped No N/A
TP53RTG8 ENSLAFG00000027820 294 Unmapped Yes 210aa
TP53RTG9 ENSLAFG00000027669 786 Unmapped No N/A
TP53RTG10 ENSLAFG00000030555 221 Unmapped Yes 210aa
TP53RTG11 N/A 281 Yes 203aa
TP53RTG12 ENSLAFG00000028299 825 Unmapped Yes 180aa
TP53RTG13 ENSLAFG00000032042 458 Unmapped No N/A
TP53RTG14 ENSLAFG00000026238 928 Unmapped Yes 210aa
TP53RTG15 ENSLAFG00000027365 656 Unmapped Yes 210aa
TP53RTG16 ENSLAFG00000030880 378 Unmapped No N/A
TP53RTG17 ENSLAFG00000028692 552 Unmapped Yes 111aa
TP53RTG18 N/A 498 Unmapped Yes 111aa
TP53RTG19 ENSLAFG00000032258 342 Unmapped Yes 210aa
DOI: 10.7554/eLife.11994.006
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TP53RTG copy number expansion is correlated with proboscidean body
size
Our observation that TP53RTG genes expanded through segmental duplications suggests they may
have a tree-like phylogenetic history that preserves information about when in the evolution of Pro-
boscideans the duplicates occurred. Therefore we assembled a dataset of TP53/TP53RTG orthologs
from 65 diverse mammals and jointly inferred the TP53/TP53RTG gene tree and duplication dates in
a Bayesian framework to determine if TP53/TP53RTG copy number was correlated with body size
evolution in Proboscideans. For comparison, we also inferred the phylogenetic history of TP53/
TP53RTG genes using maximum likelihood and an additional Bayesian method. We found all phylo-
genetic inference methods inferred that the TP53RTG genes from elephant, hyrax, and manatee
formed a well-supported sister clade to the canonical genes from these species, whereas the tenrec
TP53 and TP53RTG genes formed a separate well-supported clade (Figure 4A and Figure 4—figure
supplement 1). These data indicate that retrotransposition of TP53 occurred independently in ten-
recs and in the elephant, hyrax, and manatee stem-lineage (Paenungulata), followed by expansion of
TP53RTG genes in the Proboscidean lineage.
Based on our time-calibrated phylogeny, we inferred that the initial retrotransposition of the
TP53 gene in the Paenungulata stem-lineage occurred approximately 64 MYA (95% HPD = 62.3–
66.2 MYA; Figure 4A). This was followed by a period of ~25 million years during which no further
retrotranspositions or segmental duplications were fixed in the genome, however, the TP53RTG
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The following figure supplement is available for figure 4:
Figure supplement 1. TP53/TP53RTG gene trees.
DOI: 10.7554/eLife.11994.009
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gene family rapidly expanded after ~40 MYA (95% HPD = 30.8–48.6 MYA; Figure 4A). To correlate
TP53/TP53RTG copy number and the origin of large body sizes in Proboscideans we estimated
TP53/TP53RTG copy number through time and gathered data on ancient Proboscidean body sizes
from the literature (Evans et al., 2012; Smith et al., 2010). We found that the increase in TP53/
TP53RTG copy number in the Proboscidean lineage and Proboscidean body size evolution closely
mirrored each other (Figure 4B).
TP53RTG12 is transcribed from a transposable element derived
promoter
If expansion of the TP53RTG gene repertoire played a role in the resolution of Peto’s paradox dur-
ing the evolution of large bodied Proboscideans, then one or more of the TP53RTG genes should
be transcribed. Therefore we generated RNA-Seq data from Asian elephant dermal fibroblasts, Afri-
can elephant term placental villus and adipose tissue, and used previously published RNA-Seq data
from Asian elephant PBMCs (Reddy et al., 2015) and African elephant fibroblasts (Cortez et al.,
2014) to determine if TP53RTG genes were transcribed. We found that the TP53 and TP53RTG12
genes were robustly transcribed in all samples, whereas TP53RTG3 and TP53RTG18 transcripts were
much less abundant (Figure 5A). To confirm that the African and Asian elephant TP53RTG genes
were transcribed, we designed a set of PCR primers specific to the TP53 and TP53RTG genes that
flank a diagnostic 15–30 bp deletion in TP53RTG genes (Figure 5—figure supplement 1) and used
RT-PCR to assay for expression in Elephant fibroblast cDNA generated from DNase treated RNA.
Consistent with transcription of the TP53RTG genes, we amplified PCR products at the expected
size for the TP53 and TP53RTG transcripts but did not amplify PCR products from negative control
(no reverse transcriptase) samples (Figure 5B). Sanger sequencing of the cloned PCR products con-
firmed transcription of TP53RTG12 and TP53RTG18/19 (Figure 5—figure supplement 1) in African
elephant and TP53RTG12 and TP53RTG13 in Asian elephant fibroblast. We note that we used a
Poly-T primer for cDNA synthesis, thus the amplification of TP53RTG transcripts indicates that these
transcripts are poly-adenylated.
Most retrogenes lack native regulatory elements such as promoters and enhancers to initiate tran-
scription, thus transcribed TP53RTG genes likely co-opted existing regulatory elements or evolved
regulatory elements de novo. To identify putative transcriptional start sites and promoters of the
highly expressed TP53RTG12 gene we used geneid and GENESCAN to computationally predict
exons in the African elephant gene and mapped the African and Asian elephant fibroblast RNA-Seq
data onto scaffold_825, which encodes the TP53RTG12 gene. We found that both computational
methods predicted an exon ~2 kb upstream of the ENSEMBL annotated TP53RTG12 gene, within an
RTE-type non-LTR retrotransposon (RTE1_LA) that we annotated as Afrotherian-specific (Figure 5C).
Consistent with this region encoding a transcribed 5’-UTR, a peak of reads mapped within the pre-
dicted 5’-exon and within the RTE1_LA retrotransposon (Figure 5C).
We attempted to identify the transcription start site of the TP53RTG12 gene using several 5’-
RACE methods, however, we were unsuccessful in generating PCR products from either African Ele-
phant fibroblast or placenta cDNA, or Asian elephant fibroblast cDNA. Therefore, we designed a set
of 34 PCR primers tiled across the region of scaffold_825 that encodes the TP53RTG12 gene and
used these primers to amplify PCR products from African and Asian Elephant fibroblast cDNA gen-
erated from DNase treated RNA. We then reconstructed the likely TP53RTG12 promoter, transcrip-
tion start site, and exon-intron structure from the pattern of positive PCR products. These data
suggest that the major transcription initiation site of TP53RTG12 is located within a RTE1_LA class
transposable element (Figure 5C).
Next we tested the ability of the African and Asian elephant RTE1_LA elements and the RTE1_LA
consensus sequence (as a proxy for the ancestral RTE1_LA sequence) to function as a promoter in
transiently transfected African and Asian elephant fibroblasts when cloned into the promoterless
pGL4.10[luc2] luciferase reporter vector. We found that the African and Asian elephant RTE1_LA ele-
ments increased luciferase expression 3.03-fold (t-test, p=2.41  10–8) and 1.37-fold (t-test,
p=2.60  10–4), respectively, compared to empty vector controls (Figure 5D). However, luciferase
expression from the pGL4.10[luc2] vector containing the RTE1_LA sequence was not significantly dif-
ferent than the empty vector control in either Asian (0.96-fold; t-test, p=0.61) or African elephant
fibroblasts (0.95-fold; t-test, p=0.37; Figure 5D). These data indicate that transcription of
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the consensus of each element. PCR tiles across this region are shown for African (Lox.) and Asian (Ele.) elephants, PCR primers generating amplicons
are shown in red. The inferred TP53RTG12 transcript is shown below. one kb scale shown from position one of African elephant (Broad/loxAfr3)
scaffold_825. (D) Relative luciferase (Luc.) expression in Asian and African fibroblasts transfected with either the promoterless pGL4.10[luc2] luciferase
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TP53RTG12 likely initiates within a RTE1_LA-derived promoter, but that the ability of this RTE1_LA
element to function as a promoter is not an ancestral feature of RTE1_LA elements.
Elephant cells likely express TP53RTG proteins and numerous isoforms
of TP53
To determine if TP53RTG transcripts are translated, we treated African elephant, Asian elephant,
and hyrax cells with 50 J/m2 UV-C (to stabilize TP53) and the proteasome inhibitor MG-132 (to block
protein degradation), and assayed for TP53/TP53RTG proteins by Western blotting total cell protein
with a polyclonal TP53 antibody (FL-393) that we demonstrated recognizes Myc-tagged TP53RTG12.
We identified bands in both African and Asian elephant and hyrax total cell protein at the expected
size for the full length p53, D133 p53b/g, and p53y-like isoforms of the TP53 protein (Khoury and
Bourdon, 2010) as well as high molecular weight bands corresponding to previously reported SDS
denaturation resistant TP53 oligomers (Cohen et al., 2008; Ottaggio et al., 2000) and (poly)ubiqui-
tinated TP53 congugates (Sparks et al., 2014) (Figure 5E). We also identified an elephant-specific
band at the expected size for the TP53RTG12 (19.6 kDa) and TP53RTG19 (22.3 kDa) proteins, sug-
gesting that the TP53RTG12 and TP53RTG19 transcripts are translated in elephant fibroblasts
(Figure 5Eand Figure 5—figure supplement 2).
Elephant cells have an enhanced TP53-dependent DNA-damage
response
Our observation that TP53RTG genes are expressed suggests that elephant cells may have an
altered TP53 signaling system compared to species without an expanded TP53/TP53RTG gene rep-
ertoire. To directly test this hypothesis we transiently transfected primary African elephant, Asian
elephant, South African Rock hyrax (Procavia capensis capensis), East African aardvark (Orycteropus
afer lademanni), and Southern Three-banded armadillo (Tolypeutes matacus) dermal fibroblasts with
a luciferase reporter vector containing two TP53 response elements (pGL4.38[luc2p/p53 RE/Hygro])
and Renilla control vector (pGL4.74[hRluc/TK]). Next we used a dual luciferase reporter assay to
measure the activation of the TP53 pathway in response to treatment with three DNA damage
inducing agents (mitomycin C, doxorubicin, or UV-C) or nutlin-3a, which inhibits the interaction
between MDM2 and TP53 and thus promotes TP53 signaling. We found that elephant cells generally
up-regulated TP53 signaling in response to lower doses of each drug and UV-C than closely related
species without an expanded TP53 gene repertoire (Figure 6A), indicating elephant cells have
evolved an enhanced TP53 response.
To determine the consequences of an enhanced TP53 response we treated primary African and
Asian elephant, hyrax, aardvark, and armadillo dermal fibroblasts with mitomycin C, doxorubicin,
nutlin-3a, or UV-C and measured cell viability (live-cell protease activity), cytotoxicity (dead-cell pro-
tease activity), and the induction apoptosis (caspase-3/7 activation) using an ApoTox-Glo Triplex
assay. Consistent with the results from the luciferase assay, we found that lower doses of mitomycin
C or doxorubicin induced apoptosis in elephant cells than the other species (Figure 6B) and that the
magnitude of the response was greater in elephant than other species (Figure 6A). Similarly UV-C
exposure generally induced more elephant cells to undergo apoptosis than other species
(Figure 6A). A striking exception to this trend was the response of elephant cells to the MDM2
Figure 5 continued
reporter vector (empty vector), pGL4.10 containing the RTE_LA consensus sequences (Consensus), pGL4.10 containing the RTE_LA from Asian elephant
(Ele. RTE_LA), or pGL4.10 containing the RTE_LA from African elephant (Lox. RTE_LA). Results are shown as fold difference in Luc. expression
standardized to empty vector and Renilla controls. n = 16, Wilcoxon P-values. (E) Western blot of total cell protein isolated from South African Rock
hyrax, Asian elephant (Elephas), and African elephant (Loxodona) dermal fibroblasts.  , control cells. +, cells treated with 50 J/m2UV-C and the
proteasome inhibitor MG-132. The name and predicted molecular weights of TP53 isoforms are shown.
DOI: 10.7554/eLife.11994.010
The following figure supplements are available for figure 5:
Figure supplement 1. PCR and Sanger sequencing confirm TP53RTG12 is transcribed in elephant fibroblasts.
DOI: 10.7554/eLife.11994.011
Figure supplement 2. Unedited Western blots shown in Figure 5E.
DOI: 10.7554/eLife.11994.012
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antagonist nutlin-3a, which elicited a strong TP53 transcriptional response (Figure 6A) but did not
induce apoptosis (Figure 6B). Thus we conclude that elephant cells generally upregulate TP53 sig-
naling and apoptosis at lower levels of DNA-damage than other species, but are resistant to nutlin 3
a induced apoptosis.
TP53RTG genes are required for enhanced TP53 signaling and DNA-
damage responses
To test if TP53RTG genes are necessary for the enhanced TP53-dependent DNA-damage response,
we cotransfected African elephant fibroblasts with the pGL4.38[luc2p/p53 RE/Hygro] luciferase
reporter vector, the pGL4.74[hRluc/TK] Renilla control vector, and either a TP53RTG-specific siRNA
or a scrambled siRNA control (Figure 7A). Next we used a dual luciferase reporter assay to measure
the activation of the TP53 pathway in response to treatment mitomycin C, doxorubicin, UV-C, or nut-
lin-3a. As expected given our previous results, we found that African elephant fibroblasts transfected
with control siRNA induced TP53 signaling in response to each treatment (Figure 7A). In contrast,
African elephant fibroblasts transfected with TP53RTG-specific siRNA had significantly lower lucifer-
ase expression, and thus reduced TP53 signaling, in response to either DNA-damaging agents (mito-
mycin C, doxorubicin, UV-C) or MDM2 antagonism (nutlin-3a). TP53RTG knockdown also elevated
baseline TP53 signaling (Figure 7B). These data suggest that TP53RTG proteins have at least two
distinct functions, inhibiting TP53 signaling in the absence of inductive signals and potentiation of
TP53 signaling after the induction of DNA damage.
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Figure 6. Elephant cells have enhanced TP53 signaling and are hyper-responsive to DNA damage. (A) Relative luciferase (Luc.) expression in African
elephant, Asian elephant, hyrax, aardvark, and armadillo fibroblasts transfected with the pGL4.38[luc2p/p53 RE/Hygro] reporter vector and treated with
either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data are shown as fold difference in Luc. expression 18 hr after treatment standardized to species
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TP53RTG12 enhances TP53 signaling and DNA-damage responses via a
transdominant mechanism
To test if TP53RTG12 is sufficient to mediate enhanced TP53 signaling and DNA-damage responses
we synthesized the African elephant TP53RTG12 gene (with mouse codon usage) and cloned it into
the mammalian expression vector pcDNA3.1(+)/myc-His. We then transiently transfected mouse
3T3-L1 cells with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector and used the pGL4.38
[luc2P/p53 RE/Hygro] reporter system and ApoToxGlo assays to monitor activation of the TP53 sig-
naling pathway and the induction of apoptosis in response to treatment with mitomycin C, doxorubi-
cin, nutlin-3a, or UV-C. We found that heterologous expression of TP53RTG12 in mouse 3T3-L1 cells
dramatically augmented luciferase expression from the pGL4.38[luc2P/p53 RE/Hygro] reporter vec-
tor in response to each treatment (Figure 8A) compared to empty vector controls, consistent with a
enhancement of the endogenous TP53 signaling pathway. Similarly, expression of TP53RTG12 signif-
icantly augmented the induction of apoptosis in response to each treatment although the effect sizes
were modest (Figure 8B). These data indicate that TP53RTG12 acts via a trans-dominant mechanism
to enhance the induction of apoptosis by endogenous TP53 and that TP53RTG12 is sufficient to
recapitulate at least some of the enhanced sensitivity of elephant cells to DNA damage. Further-
more, our observation that transfection with the TP53RTG12 pcDNA3.1(+)/myc-His expression vec-
tor augments TP53 signaling and apoptosis suggests that the TP53RTG12 protein rather than
transcript is responsible for these effects because the TP53RTG12 transgene was synthetized with
mouse codon usage and is only 73% (394/535 nts) identical to the elephant TP53RTG12 gene.
TP53RTG proteins are unlikely to directly regulate TP53 target genes because they lack critical
residues required for nuclear localization, tetramerization, and DNA-binding (Figure 9A). Previous
studies, for example, have shown the TP53 mutants lacking the tetramerization domain and C-termi-
nal tail are unable to bind DNA or transactivate luciferase expression from a reporter vector contain-
ing TP53 response elements (Kim et al., 2012). Similarly the p53	 isoform, which is truncated in the
middle of the DNA binding domain and lacks the nuclear localization signal and oligomerization
domain, is unable to bind DNA and is transcriptionally inactive (Senturk et al., 2014). Unexpectedly,
we found that the GFP-tagged TP53RTG12 protein was both cytoplasmic and nuclear localized in
transfected African elephant fibroblasts (Figure 9B), suggesting it interacts with another nuclear
localized protein to enter the nucleus. Despite relatively strong nuclear localization, however, cells
co-transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector and the pGL4.38[luc2P/
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Figure 7. TP53RTG genes are required for enhanced TP53 signaling and DNA-damage responses. (A) Expression of TP53RTG and TP53 transcripts in
African elephant fibroblasts treated with an siRNA to knockdown the expression of TP53RTG genes (red) or a scrambled (Control) siRNA (blue). Results
are shown as fold-change in TP53RTG and TP53 transcript abundance relative to transcript abundance in scrambled siRNA control cells. The TP53RTG
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expression in African elephant fibroblasts transfected with the pGL4.38[luc2p/p53 RE/Hygro] reporter vector and treated with an siRNA to knockdown
the expression of TP53RTG genes (red) or a scrambled (negative control) siRNA (blue), and treated with either mitomycin c, doxorubicin, nutlin-3a, or
UV-C. Data is shown as fold difference in Luc. expression 18 hr after treatment standardized to Renilla controls and no treatment. n > 4, mean±SD. **,
Wilcoxon p>0.01. ***, Wilcoxon p>0.001.
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p53 RE/Hygro] luciferase reporter vector did not have elevated luciferase expression compared to
controls, suggesting that TP53RTG12 is transcriptionally inactive or requires a cofactor to regulate
target genes (Figure 9C).
A model for TP53RTG function – decoy or guardian?
While TP53RTG12 does not appear to directly regulate gene expression, many of the TP53RTG pro-
teins (including TP53RTG12) retain the MDM2 interaction motif in the transactivation domain and
dimerization sites in the DNA binding domain (Figure 9A). These data suggest at least two non-
exclusive models of TP53RTG action: (1) TP53RTG proteins may act as ‘decoys’ for the MDM2 com-
plex allowing the canonical TP53 protein to escape negative regulation (Figure 10A); and (2)
TP53RTG proteins may protect canonical TP53 from MDM2 mediated ubiqutination, which requires
tetramerization (Kubbutat et al., 1998; Maki, 1999), by dimerizing with canonical TP53 and thereby
preventing the formation of tetramers (Figure 10F).
The decoy model depends on the ability of TP53RTG proteins to physically interact with MDM2.
Previous crystallographic studies of the TP53/MDM2 interaction have shown that a trio of residues in
TP53 (F19, W23, and L26) insert deeply into a hydrophobic cleft in MDM2, which stabilizes the inter-
action (Kussie et al., 1996). We identified a W23G substitution in all TP53RTG proteins at a site that
is invariant for tryptophan in TP53 proteins including African and Asian elephant TP53 (Figure 10B),
suggesting that TP53RTG proteins may be unable to physically interact with MDM2. To infer the
structural and functional consequences of the TP53RTG W23G substitution we generated a homol-
ogy model of the elephant TP53RTG12/MDM2 complex using I-TASSER/ModRefiner (Roy et al.,
2010; Xu and Zhang, 2011; Zhang, 2008) and the crystal structure of the MDM2/TP53 dimer as a
template (Kussie et al., 1996). We found that the TP53RTG12 transactivation domain was inferred
2
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to be a short a-helix (Figure 10C) and was very similar to the template structure (RMSD: 1.756),
however, the W23G substitution is predicted to abolish crucial hydrophobic interactions between
the amphipathic a-helix of TP53 and the hydrophobic cleft MDM2. Indeed, three methods
(Pires et al., 2014) inferred that the W23G substitution is destabilizing on the TP53RTG12/MDM2
interaction (mCSM DDG =  2.42, SDM DDG =  5.46, DUET DDG =  2.38) (Figure 10D). To experi-
mentally test for an interaction between TP53RTG12 and MDM2 we transiently transfected HEK-293
cells with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector, immunoprecipitated endoge-
nous human MDM2, and assayed for co-immunoprecipitation of TP53RTG12 by Western blotting.
While we efficiently co-immunoprecipitated endogenous human TP53 we did not co-immunoprecipi-
tate Myc-tagged TP53RTG12 (Figure 10Eand Figure 10—figure supplement 1), consistent with a
lack of interaction between TP53RTG12 and MDM2.
Unlike the decoy model, the guardian model of TP53RTG function depends upon a physical inter-
action between TP53RTG and TP53. The TP53 dimer is stabilized by hydrophobic and polar interac-
tions including a shell of nonpolar interactions formed by P177, H178, M243, and G244 and a
stabilization network next to the nonpolar layer formed by charged residues from the two monomers
(R181, E180, and R174). In addition, several polar and charged residues nearby but not within the
dimerization interface contribute to the stability of the interacting monomers including D184 with
R175, most of which are conserved in TP53RTG proteins (Figure 10G). To infer if derived residues in
the TP53RTG12 dimerization interface might disrupt a physical interaction between TP53RTG12 and
TP53 we generated a homology model of the TP53RTG12/TP53 dimer using I-TASSER/ModRefiner
(Roy et al., 2010; Xu and Zhang, 2011; Zhang, 2008) and the crystal structure of the TP53 tetramer
as a template (Kitayner et al., 2006). We found that the TP53RTG12 dimerization interface was
inferred to be a 2–4 residue a-helix (Figure 10H) that was nearly identical to the template structure
(RMSD: 0.605), suggesting TP53RTG12-specific residues in dimerization interface are unlikely to dis-
rupt the structure of the interface. Unlike the MDM2 interaction site, TP53RTG12-specific substitu-
tions were predicted to maintain intermolecular hydrophobic interactions with TP53 (Figure 10H).
Consistent with maintenance of dimerization potential, the net DDG of the derived amino acid substi-
tutions in the TP53RTG12 dimerization interface were under 2 (Figure 10I). To experimentally test
for an interaction between TP53RTG12 and TP53 we transiently transfected HEK-293 cells with the
TP53RTG12 pcDNA3.1(+)/myc-His expression vector, immunoprecipitated TP53RTG12 with a Myc
antibody, and assayed for co-immunoprecipitation of endogenous human TP53 by Western blotting.
We found that Myc-tagged TP53RTG12 efficiently co-immunoprecipitated endogenous human TP53
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Figure 10. TP53RTG12 interacts with TP53 but not MDM2. (A) Decoy model of TP53RTG12 function. Under normal conditions TP53 is negatively
regulated by the MDM complex which ubiquitinates TP53 tetramers leading to proteosomal degradation. Upon DNA damage TP53 is phosphorylated,
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dimerize with canonical TP53 and block formation of TP53 tetramers. These TP53RTG12/TP53 dimers cannot be ubiquitinated generating a pool of
TP53 proteins to rapidly respond to lower levels or DNA damage and stress than other species. (G) Logo of the dimerization domain of TP53 from 99
mammals (upper) and TP53RTG proteins (lower). (H) Model of the TP53/TP53RTG12 interaction. Residues critical for dimerization are shown as spheres,
note sites involved in dimerization are conserved in TP53RTG proteins. (I) Predicted effects of the W23G substitution (DDG) on the stability of the
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(Figure 10J). These data are consistent with a physical interaction between TP53RTG12 and TP53
but not between TP53RTG12 and MDM2, supporting the guardian model.
Discussion
A major developmental and life history constraint on the evolution of large body sizes and long life-
spans in animals is an increased risk of developing cancer. There is no correlation, however, between
body size or lifespan and cancer risk because large and long-lived organisms have evolved enhanced
cancer suppression mechanisms that delay the development of cancer until post-reproduction (when
selection generally cannot act). This simple evolutionary rational demands mechanistic explanations
(Peto, 2015), which have thus far been elusive. Here we show that the master tumor suppressor
TP53, which is essential for preventing cancer because it triggers proliferative arrest and apoptosis
in response to a variety of stresses such as DNA damage, was retroduplicated in the Paenungulate
stem-lineage and rapidly increased in copy number through repeated segmental duplications during
with the evolution of Proboscideans. The expansion of the TP53RTG gene family occurred coincident
with the evolution of large body sizes and enhanced sensitivity of elephant cells to genotoxic stress,
suggesting that Proboscideans resolved Peto’s paradox at least in part through the evolution of aug-
mented TP53 signaling.
Comparison to previous studies of elephant TP53
Previous studies have suggested that the TP53 gene family expanded in the elephant lineage
(Abegglen et al., 2015; Caulin and Maley, 2011; Caulin et al., 2015), however, these studies did
not establish the mechanism by which the TP52RTG gene family expanded. Several potential mecha-
nisms could have increased TP52RTG copy number, including serial (independent) retrotranspostion
from the parent TP53 gene, a single retrotranspostion event followed by repeated rounds of seg-
mental duplication of TP52RTG containing loci, retrotransposition of expressed TP52RTG genes, or
some combination of these models. Each model is associated with a distinct set of genomic ‘finger-
prints’. If copy number expanded through independent retrotransposition events, for example,
TP53RTG encoding regions of the genome will not be homologous whereas the model of a single
retrotranspostion event followed by repeated rounds of segmental duplication predicts that the
TP53RTG encoding loci will be homolgous. Consistent with copy number expansion through a single
retrotransposition event followed by repeated rounds of segmental duplication, we found that flak-
ing regions of each TP52RTG locus were homologous and contained the same unique combination
of transposable elements. Indeed, the 3’-end of each duplicate terminates at a ~5 kb long L1MB5
LINE element suggesting that transposable element mediated recombination may have played a
role in promoting segmental duplication.
If TP53RTG copy number expansion played a causal role in evolution of enhanced cancer resis-
tance in elephants then the gene family must have expanded prior to or coincident with the evolu-
tion of increased body sizes in Proboscideans rather than after the evolution of large bodies but
before the African and Asian elephant lineages diverged ~8 MYA (Rohland et al., 2010, 2007). Thus
dating the expansion of the TP53RTG gene family is essential for determining if TP53RTG genes
played a role in the evolution of enhanced cancer resistance in elephants. Previous studies, however,
did not establish when TP53RTG copy number expanded in the evolution of Proboscideans. Fortu-
nately our observation that copy number expansion occurred through segmental duplications
allowed us to use molecular phylogenetic methods to date each duplication event. These data indi-
cate that the initial TP53RTG retrotransposition event occurred in the Paenungulate stem-
Figure 10 continued
MDM2/TP53RTG12 interaction estimated with mCSM, SDM, and DUET. (J) HEK-293 cells were transiently transfected with the TP53RTG12 pcDNA3.1
(+)/myc-His expression vector and total cell protein immunoprecipitated with an a-Myc antibody. Co-immunoprecipitation of TP53 and MDM2 were
assayed by serial Western blotting with a-Myc, a-TP53, and a-MDM2 antibodies after chemically stripping the blot, respectively.
DOI: 10.7554/eLife.11994.017
The following figure supplement is available for figure 10:
Figure supplement 1. Uncropped Western blots shown in Figure 8B.
DOI: 10.7554/eLife.11994.018
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lineage ~ 64 MYA, followed the rapid expansion after ~40 MYA. We also found that the increase in
TP53RTG copy number occurred coincident with the evolution of large bodies in the Proboscidean
lineage, implicating copy number expansion in the resolution of Peto’s paradox.
While Abegglen et al. (2015) found that elephant and human cells had different sensitivities to
ionizing radiation, their taxon sampling did not allow for polarizing which species was different.
Indeed, their taxon sampling does not allow for a Eutherian out-group. To determine if elephants
have a derived sensitivity to genotoxic stress, we compared the response of fibroblasts from an Afri-
can savannah elephant, an Asian elephant, and closely related out-group species to DNA damage
inducing agents. Our out-group species included the South African Rock hyrax, the closest living rel-
ative of elephants, the East African aardvark, an Afrotherian from the sister lineage of the Paenungu-
lates, and the Southern Three-banded armadillo, an Atlantogenatan from the sister lineage of the
Afrotherians. Our results indicate that elephant cells are particularly sensitive to genotoxic tress, sug-
gesting that this sensitivity evolved coincident with the evolution of large body sizes and an
expanded TP53 gene repertoire in Proboscideans.
An embarrassment of riches?
Our observation that the elephant genome contains 19 TP53RTG genes raises numerous questions:
Do these loci, for example, encode functional genes or pseudogenes and what processes underlie
copy number expansion? Answers to these questions are essential for understanding whether
TP53RTG genes are casually related to the resolution of Peto’s paradox in Proboscideans or if they
are irrelevant relicts of ancient transposition events, like so many other pseudogenes that riddle
mammalian genomes. Unfortunately, it is difficult to answer these questions.
Which TP53RTG loci encode functional genes and which encode pseudogenes is not easy to infer.
Many duplicate genes are preserved because they evolve tissue-specific or developmental-stage
specific expression patterns (subfunctionalization), new functions (neofunctionalization) that resolve
redundancy between duplicates, or reduced expression levels that preserves correct expression dos-
age. Exhaustively characterizing gene expression in elephant tissues is difficult because appropriate
tissue samples are unavailable, therefore we are unable to definitively determine which TP53RTG
loci are transcribed. Our RNA-Seq and RT-PCR/Sanger sequencing data indicate that at least
TP53RTG12, TP53RTG18/19, and TP53RTG13 are transcribed in dermal fibroblasts. Abegglen et al.
(2015) used RT-PCR and Sanger sequencing to show two distinct transcripts were expressed in ele-
phant PBMCs, but they did not assign the loci to which these transcripts correspond. We analyzed
the chromatograms shown in Abegglen et al. Figure 4 and found that the 185 bp product is likely a
transcript from the TP553RTG14 gene and the 201 bp product is likely a transcript from the
TP553RTG5 gene. Thus, our combined data suggest that at least five TP53RTG genes are tran-
scribed. Furthermore we did not observe TP553RTG14 or TP553RTG5 expression in adipose, pla-
centa, or fibroblasts suggesting that the expression of some TP53RTG genes is tissue-specific.
The large number of TP53RTG loci in elephants combined with the observation that only five are
transcribed suggests that this gene family may evolve by a birth and death process, in which new
genes are created by duplication and some duplicates are maintained in the genome whereas others
become nonfunctional or deleted similar to other large genes families such as histones (Gonza´lez-
Romero et al., 2010; Rooney et al., 2002) and venom genes (Lynch, 2007). Under this model selec-
tion acts to maintain a minimal number of functional copies (functional copy number) rather than
total copy number, the increase in total copy number is driven by the total number of loci and the
rates of duplication, loss, and fixation. Thus the overall increase in total TP53RTG copy number may
be a selectively neutral process, driven simply by higher rates of duplication and/or fixation than
loss.
Is TP53RTG12 a decoy, a guardian, or something else?
Our results demonstrate that elephant cells induce TP53 signaling and trigger apoptosis at lower
thresholds of genotoxic stress than closely related species without an expanded TP53 repertoire and
that this reduced sensitivity is dependent upon TP53RTG genes. Furthermore, heterologous expres-
sion of TP53RTG12 in mouse cells was sufficient to augment endogenous TP53 signaling and reca-
pitulate an elephant-like sensitivity to genotoxic stress, indicating that TP53RTGs acts through a
transdominant mechanism. While the mechanism of action is unclear, TP53RTG genes may augment
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TP53 signaling through several non-exclusive mechanisms including functioning as non-coding RNAs
(Poliseno et al., 2010), protein ‘decoys’ for the MDM2 complex that allowing canonical TP53 to
escape negative regulation (Abegglen et al., 2015), and protein ‘guardians’ that protect canonical
TP53 from MDM2 mediated ubiqutination.
Consistent with the guardian model, we found that Myc-tagged TP53RTG12 efficiently co-immu-
noprecipitated with endogenous TP53 but not with endogenous MDM2. The lack of an interaction
between TP53RTG12 and MDM2 likely results from a W23G substitution that is predicted to abolish
a crucial hydrophobic interaction between the amphipathic a-helix of TP53 and the hydrophobic
cleft MDM2. The W23G substitution is found in all TP53RTG proteins but not African and Asian ele-
phant TP53, indicating that it occurred before the expansion of the TP53RTG gene family and likely
prevents interaction of any TP53RTG protein and MDM2. Previous studies have shown that tetrame-
rization of TP53 is required for its efficient MDM2-mediated ubiquitination (Kubbutat et al., 1998;
Maki, 1999), suggesting that TP53RTG proteins may dimerize with and protect TP53 from ubiquiti-
nation thereby contributing to a standing pool of TP53 that is able to rapidly respond to DNA dam-
age. Consistent with this mechanism, transgenic mice with an increase in TP53 copy number (Garcı´a-
Cao et al., 2002) or a hypomorphic Mdm2 allele have elevated basal TP53 activity and are resistant
to tumor formation (Mendrysa et al., 2006), indicating that shifting the TP53-MDM2 equilibrium
away from TP53 degradation can directly promote cancer resistance.
The ‘decoy’ model (Abegglen et al., 2015) has also been challenged because it would allow for
activation of the TP53 signaling pathway in the absence of DNA damage (Perez and Komiya,
2016), which is generally lethal in animal models (Hoever et al., 1994; Lozano, 2010). Thus if
TP53RTG proteins allow TP53 to escape negative regulation by MDM2, how do elephants tolerate
elevated basal TP53 levels? Clearly further studies are required to specifically test whether TP53RTG
proteins interfere with the interaction between the MDM2 complex and TP53, protect TP53 from
ubiquitination, or have other functions.
What do extra TP53 genes cost?
Our observation reveals that functional TP53 duplicates only occur in the elephant lineage (and per-
haps some bats) suggests that increased TP53 dosage has a cost. Previous studies found that trans-
genic mice that overexpress Trp53 were cancer resistant but had major life history tradeoffs
including slower pre- and post-natal growth rates and reduced size (Maier et al., 2004), a shortened
lifespan (Maier et al., 2004), accelerated aging (Tyner et al., 2002), and reduced fertility
(Allemand et al., 1999; Maier et al., 2004), as well as developmental tradeoffs including reduced
proliferation, cellularity, and atrophy across multiple organ and tissue systems (Dumble et al., 2007;
Maier et al., 2004), defective ureteric bud differentiation, and small kidneys (Godley et al., 1996).
Thus, increases in TP53 copy number protects against cancer but appears to come with the cost of
developmental delays, accelerated aging, and reduced fertility (Campisi, 2003; Donehower, 2002;
Ferbeyre and Lowe, 2002; Rodier et al., 2007).
Reduced male fertility appears to be a particularly expensive cost of increased TP53 dosage.
Allemand et al., 1999), for example, generated transgenic lines of mice with one (MTp53-176), two
(MTp53-112), or 15 (MTp53-94) extra copies of the Trp53 gene fused to the inducible promoter of
the metallothionein I (MT) gene. They found that transgenic males with the highest Trp53 dosage
were nearly infertile because the majority of developing spermatids underwent apoptosis before
developing into mature sperm, males with intermediate dosage were subfertile and produced sperm
with abnormal morphologies (teratozoospermia) indicative of defective terminal differentiation of
postmeiotic cells, whereas males with the lowest dosage were fertile. Similarly, Maier et al. (2004)
generated a transgenic line that overexpresses the p44 isoform of Trp53 (D40 p53) and found that
both males and females exhibited shortened reproductive lifespans. Males, however, were more
severely affected than females with a catastrophic loss of sperm-producing cells and massive degen-
eration of the seminiferous epithelium leading to a ’Sertoli-cell only’ phenotype.
In contrast to transgenic mice that either overexpress full length TP53 or the D40 p53 isoform,
transgenic ’super p53’ mice with one (p53-tg) or two (p53-tgb) additional copies of the endogenous
TP53 locus have an enhanced DNA-damage response and are tumor resistant, yet age normally and
are fertile (Garcı´a-Cao et al., 2002, 2006; Matheu et al., 2007). Enhanced tumor suppression and
normal aging is also observed in Mdm2puro/D7–12 transgenic mice, which have one hypomorphic and
one null allele of Mdm2, express ~30% of the wild-type level of Mdm2, and have constitutively high
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TP53 activity (Mendrysa et al., 2006, 2003). These results suggest that the costs of increased TP53
copy number are incurred above a threshold of about 2–3 extra copies and can be reduced by main-
taining normal regulation of TP53 transcription and negative post-transcriptional regulation by
MDM2. Consistent with this model, deletion of either Mdm2 or Mdm4 rescues Trp53-dependent
embryonic lethality in mice (Finch et al., 2002; Migliorini et al., 2002; Parant et al., 2001) and
zebrafish (Chua et al., 2015).
Collectively, these data indicate that increased TP53 dosage comes with a cost, and suggest that
Proboscideans evolved a mechanism that reduced this cost, broke a major developmental and evolu-
tionary constraint on TP53 copy number, or perhaps evaded paying the cost of increased TP53 copy
number altogether. TP53RTG genes, for example, are transcribed from a transposable element
derived promoter that is evolutionarily younger than the retrogenes. Thus, the initial TP53RTG genes
were unlikely to be transcribed and incur a cost. Similarly, our phylogenetic analyses indicates that
copy number expanded after the initial TP53RTG gene acquired several mutations, including a pre-
mature stop codon that terminates the protein before the DNA-binding domain, which likely reduces
or completely eliminates the costs associated with TP53 target gene regulation. Although more
detailed evolutionary and comparative analyses are required to determine if TP53RTG genes
incurred a cost, it is possible that the costs were minimized because functional TP53RTG genes
evolved through non-functional intermediates, which accumulated loss of function mutations that
minimized redundancy with TP53.
Materials and methods
Identification of TP53/PT53RTG genes in sarcopterygian genomes
We used BLAT to search for TP53 genes in 61 Sarcopterygian genomes using the human TP53 pro-
tein sequences as an initial query. After identifying the canonical TP53 gene from each species, we
used the nucleotide sequences corresponding to this TP53 CDS as the query sequence for additional
BLAT searches within that species genome. To further confirm the orthology of each TP53 gene we
used a reciprocal best BLAT approach, sequentially using the putative CDS of each TP53 gene as a
query against the human genome; in each case the query gene was identified as TP53. Finally, we
used the putative amino acid sequence of the TP53 protein as a query sequence in a BLAT search.
We thus used BLAT to characterize the TP53 copy number in Human (Homo sapiens; GRCh37/
hg19), Chimp (Pan troglodytes; CSAC 2.1.4/panTro4), Gorilla (Gorilla gorilla gorilla; gorGor3.1/gor-
Gor3), Orangutan (Pongo pygmaeus abelii; WUGSC 2.0.2/ponAbe2), Gibbon (Nomascus leucoge-
nys; GGSC Nleu3.0/nomLeu3), Rhesus (Macaca mulatta; BGI CR_1.0/rheMac3), Baboon (Papio
hamadryas; Baylor Pham_1.0/papHam1), Marmoset (Callithrix jacchus; WUGSC 3.2/calJac3), Squirrel
monkey (Saimiri boliviensis; Broad/saiBol1), Tarsier (Tarsius syrichta; Tarsius_syrichta2.0.1/tarSyr2),
Bushbaby (Otolemur garnettii; Broad/otoGar3), Mouse lemur (Microcebus murinus; Broad/micMur1),
Chinese tree shrew (Tupaia chinensis; TupChi_1.0/tupChi1), Squirrel (Spermophilus tridecemlineatus;
Broad/speTri2), Mouse (Mus musculus; GRCm38/mm10), Rat (Rattus norvegicus; RGSC 5.0/rn5),
Naked mole-rat (Heterocephalus glaber; Broad HetGla_female_1.0/hetGla2), Guinea pig (Cavia por-
cellus; Broad/cavPor3), Rabbit (Oryctolagus cuniculus; Broad/oryCun2), Pika (Ochotona princeps;
OchPri3.0/ochPri3), Kangaroo rat (Dipodomys ordii; Broad/dipOrd1), Chinese hamster (Cricetulus
griseus; C_griseus_v1.0/criGri1), Pig (Sus scrofa; SGSC Sscrofa10.2/susScr3), Alpaca (Vicugna pacos;
Vicugna_pacos-2.0.1/vicPac2), Dolphin (Tursiops truncatus; Baylor Ttru_1.4/turTru2), Cow (Bos tau-
rus; Baylor Btau_4.6.1/bosTau7), Sheep (Ovis aries; ISGC Oar_v3.1/oviAri3), Horse (Equus caballus;
Broad/equCab2), White rhinoceros (Ceratotherium simum; CerSimSim1.0/cerSim1), Cat (Felis catus;
ICGSC Felis_catus 6.2/felCat5), Dog (Canis lupus familiaris; Broad CanFam3.1/canFam3), Ferret
(Mustela putorius furo; MusPutFur1.0/musFur1), Panda (Ailuropoda melanoleuca; BGI-Shenzhen 1.0/
ailMel1), Megabat (Pteropus vampyrus; Broad/pteVam1), Microbat (Myotis lucifugus; Broad Institute
Myoluc2.0/myoLuc2), Hedgehog (Erinaceus europaeus; EriEur2.0/eriEur2), Shrew (Sorex araneus;
Broad/sorAra2), Minke whale (Balaenoptera acutorostrata scammoni; balAcu1), Bowhead Whale
(Balaena mysticetus; v1.0), Rock hyrax (Procavia capensis; Broad/proCap1), Sloth (Choloepus hoff-
manni; Broad/choHof1), Elephant (Loxodonta africana; Broad/loxAfr3), Cape elephant shrew (Ele-
phantulus edwardii; EleEdw1.0/eleEdw1), Manatee (Trichechus manatus latirostris; Broad v1.0/
triMan1), Tenrec (Echinops telfairi; Broad/echTel2), Aardvark (Orycteropus afer afer; OryAfe1.0/
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oryAfe1), Armadillo (Dasypus novemcinctus; Baylor/dasNov3), Opossum (Monodelphis domestica;
Broad/monDom5), Tasmanian devil (Sarcophilus harrisii; WTSI Devil_ref v7.0/sarHar1), Wallaby (Mac-
ropus eugenii; TWGS Meug_1.1/macEug2), Platypus (Ornithorhynchus anatinus; WUGSC 5.0.1/
ornAna1), Medium ground finch (Geospiza fortis; GeoFor_1.0/geoFor1), Zebra finch (Taeniopygia
guttata; WashU taeGut324/taeGut2), Budgerigar (Melopsittacus undulatus; WUSTL v6.3/melUnd1),
Chicken (Gallus gallus; ICGSC Gallus_gallus-4.0/galGal4), Turkey (Meleagris gallopavo; TGC Tur-
key_2.01/melGal1), American alligator (Alligator mississippiensis; allMis0.2/allMis1), Painted turtle
(Chrysemys picta bellii; v3.0.1/chrPic1), Lizard (Anolis carolinensis; Broad AnoCar2.0/anoCar2), X.
tropicalis (Xenopus tropicalis; JGI 7.0/xenTro7), Coelacanth (Latimeria chalumnae; Broad/latCha1).
TP53/TP53RTG copy number estimation in proboscidean genomes
Identification of TP53/TP53RTG genes in the Asian elephant genome
We used previously published whole genome shotgun sequencing data from an Asian elephant (Ele-
phas maximus) generated on an Illumina HiSeq 2000{’Hou’} to estimate the TP53/TP53RTG copy
number in the genome. For these analyses, we combined data from two individual elephants
(ERX334765 and ERX334764) into a single dataset of 151,482,390 76-nt paired end reads. We then
mapped Asian elephant reads onto the African elephant TP53/TP53RTG genes using Bowtie2 in
paired-end mode, with the local alignment and ‘very sensitive’ options and Cufflinks (version 0.0.7)
to assemble mapped reads into genes which we treated as putative Asian elephant orthologs. We
identified 14 putative 1:1 orthologous TP53RTG genes in the Asian elephant genome, including
TP53RTG1, TP53RTG2, TP53RTG3, TP53RTG4, TP53RTG5, TP53RTG6, TP53RTG9, TP53RTG10,
TP53RTG11, TP53RTG13, TP53RTG14, TP53RTG17, TP53RTG18, and TP53RTG19.
Identification of TP53/TP53RTG genes in the Columbian and woolly
mammoth genomes
We used previously published whole genome shotgun sequencing data from an ~11,000 year old
Columbian mammoth (Mammuthus columbi) generated on an Illumina HiSeq 1000{’Sparks’} to esti-
mate the TP53/TP53RTG copy number in the genome. For these analyses, we combined data from
three individual mammoths (SRX329134, SRX329135, SRX327587, SRX327586, SRX327583,
SRX327582) into a single dataset of 158,704,819 102-nt paired end reads. We then mapped Asian
elephant reads onto the African elephant TP53/TP53RTG genes using Bowtie2 in paired-end mode,
with the local alignment and ‘very sensitive’ options, and Cufflinks (version 0.0.7) to assemble
mapped reads into genes which we treated as putative Asian elephant orthologs. We identified 14
putative 1:1 orthologous TP53RTG genes in the Columbian mammoth genome, including
TP53RTG10, TP53RTG11, TP53RTG13, TP53RTG14, TP53RTG16, TP53RTG17, TP53RTG19,
TP53RTG2, TP53RTG3, TP53RTG4, TP53RTG5, TP53RTG6, TP53RTG8, TP53RTG9.
Identification of TP53/TP53RTG genes in the American mastodon genome
We used previously published whole genome shotgun sequencing data generated on a Roche 454
Genome Sequencer (GS FLX) to estimate the TP53 copy number in a 50,000–130,000 year old Amer-
ican mastodon (Mammut americanum){’Langmead’}. To estimate TP53 copy number we combined
454 sequencing data from ‘Library A’ (SRX015822) and ‘Library B’ (SRX015823) into a single dataset
of 518,925 reads. Reads were converted from FASTQ to FASTA and aligned to African elephant
TP53 gene and retrogene sequences using Lastz. We used the ‘Roche-454 90% identity’ mapping
mode, not reporting matches lower than 90% identity. Three American mastodon reads were identi-
fied that mapped to at least one TP53 gene/retrogene. The likely identities of these reads were
determined by using BLAT to map their location in the African elephant (Broad/loxAfr3) genome;
mastodon reads mapping to a single elephant gene with >98% identity were considered likely mas-
todon orthologs. This strategy mapped one read to the TP53TRG8 retrogene, one read to the either
the TP53TRG3 or TP53RTG10 retrogenes, and one read to the TP53TRG6 retrogene.
Gene tree reconciliation
For gene tree reconciliation putative Asian elephant, Columbian mammoth, and woolly mammoth
TP53/TP53RTG orthologs were manually placed into the African elephant TP53/TP53RTG gene tree.
We then used Notung v2.6 (Trapnell et al., 2012) to reconcile the gene and species trees, and
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interpreted Asian elephant-, Columbian mammoth-, and wooly mammoth-specific gene losses as
unsampled TP53RTG genes if the putative divergence date of the ortholog predated the African-
(Asian elephant/Mammoth) divergence. We thus inferred two unsampled genes (TP53RTG7 and
TP53RTG8) in the Asian elephant genome, and three unsampled genes (TP53RTG18, TP53RTG7 and
TP53RTG1) in the Columbian mammoth genome. Note that this method will estimate the minimum
number of TP53/TP53RTG genes in the genome because our mapping strategy cannot identify line-
age specific duplications after each species diverged from the African elephant lineage. Finally, we
used Notung v2.6 (Wilkie et al., 2013) to reconcile the gene and species trees, and interpreted line-
age-specific gene losses as unsampled TP53RTG genes (i.e., genes present in the genome but miss-
ing from the aDNA sequencing data). This process was modified slightly for American mastodon,
such that ‘lost’ TP53RTG genes younger than the mastodon-elephant split were considered ele-
phant-specific paralogs rather than unsampled genes present in the mastodon genome.
Normalized read depth
We also used normalized mapped read depth to estimate TP53/TP53RTG copy number. Unlike
gene tree reconciliation, copy number estimates based on read depth cannot resolve the orthology
of specific TP53/TP53RTG copies but can estimate the total number of TP53/TP53RTG copies in the
genome and thus provide evidence of lineage specific copy number changes. For this analyses, we
mapped Asian elephant-, Columbian mammoth-, and woolly mammoth-specific reads onto the Afri-
can elephant TP53/TP53RTG genes using Bowtie 2 (Langmead and Salzberg, 2012) with the local
alignment and ‘very sensitive’ options and Cufflinks (version 0.0.7) (Trapnell et al., 2012) to assem-
ble mapped reads into genes. We then summed the read depth (‘coverage’) of TP53RTG genes and
normalized this summed TP53RTG read depth to the read depth of five single copy genomic regions
equal in length to average TP53RTG gene length. This ratio represents an estimate of the TP53/
TP53RTG copy number in the genome.
Correlation between TP53/TP53RTG copy number and body size
evolution
Relative divergence (duplication) times of the TP53 retrogenes were estimated using the TP53 align-
ment described above and BEAST (v1.7.4) (Rohland et al., 2010). We used the general time revers-
ible model (GTR), empirical nucleotide frequencies (+F), a proportion of invariable sites estimated
from the data (+I), four gamma distributed rate categories (+G), an uncorrelated lognormal relaxed
molecular clock to model substitution rate variation across lineages, a Yule speciation tree prior, uni-
form priors for the GTR substitution parameters, gamma shape parameter, proportion of invariant
sites parameter, and nucleotide frequency parameter. We used an Unweighted Pair Group Arithme-
tic Mean (UPGMA) starting tree.
To obtain posterior distributions of estimated divergence times, we use five node calibrations
modeled as normal priors (standard deviation = 1) to constrain the age of the root nodes for the
Eutheria (104.7 MYA), Laurasiatheria (87.2 MYA), Boreoeutherian (92.4 MYA), Atlantogenatan (103
MYA), and Paenungulata (64.2 MYA); divergence dates were obtained from www.timetree.org using
the ‘Expert Result’ divergence dates. The analysis was run for 5 million generations and sampled
every 1000 generations with a burn-in of 1 million generations; convergence was assessed using
Tracer, which indicated convergence was reached rapidly (within 100,000 generations). Probosci-
dean body size data were obtained from previously published studies on mammalian body size evo-
lution (Chen et al., 2000).
Inference of TP53/TP53RTG copy number expansion through segmental
duplications
We also observed that the genomic region surrounding each TP53RTG gene contained blocks of
homolgous transposable element insertions, suggesting that these regions are segmental duplica-
tions. To confirm this observation, we used MUSCLE (Edgar, 2004) to align an approximately 20 kb
region surrounding each TP53RTG gene and found that conservation within this region was very
high, again suggesting these regions are relatively recent segmental duplications. To identify if the
contigs on which TP53RTG genes are located contained locally collinear blocks (LCBs), as expected
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for segmental duplications, we aligned contigs using progressiveMAUVE (Darling et al., 2004) as
implemented in Genious (v6.1.2).
Phylogenetic analyses of TP53/TP53RTG genes
We generated a dataset of TP53 orthologs from 65 diverse mammals identified from GenBank, and
included the TP53 genes and retrogenes we identified from the African elephant, hyrax, manatee,
tenrec, cape elephant shrew, and armadillo genomes. Nucleotide sequences were aligned using the
MAFFT algorithm (Katoh and Standley, 2014) and the FFT refinement strategy implemented in the
GUIDANCE webserver (Penn et al., 2010). Alignment confidence was assessed with 100 bootstrap
replicates and ambiguously aligned sites (under the default GUIDANCE exclusion rule) removed
prior to phylogenetic analyses; lineage specific insertions and deletions were also removed prior to
phylogenetic analyses.
TP53 phylogenies were inferred using maximum likelihood implemented in PhyML (v3.1)
(Guindon et al., 2010) using a general time reversible model (GTR), empirical nucleotide frequencies
(+F), a proportion of invariable sites estimated from the data (+I), four gamma distributed rate cate-
gories (+G), and using the best of NNI and SPR branch moves during the topology search. Branch
supports were assessed using the aBayes, aLRT, SH-like, and Chi2-based ‘fast’ methods as well as
1000 bootstrap replicates (Guindon et al., 2010). We also used MrBayes (v3.2.2 x64)
(Huelsenbeck and Ronquist, 2001) for Bayesian tree inference using the GTR+I+G model; the anal-
ysis was run with two simultaneous runs of four chains for 4 million generations with the chains sam-
pled every 1000 generations. We used Tracer (v1.5) to assess when the chains reached stationarity,
which occurred around generation 100,000. At completion of the run the PRSF value was 1.00 indi-
cating the analyses had reached convergence.
Gene expression data (RNA-Seq)
To determine if TP53RTG genes were expressed, we generated RNA-Seq data from term placental
villus and adipose tissue from African elephants (Loxodonta africana) and primary dermal fibroblasts
from Asian elephants (Elepas maximus). Briefly, sequencing libraries were prepared using standard
Illumina protocols with poly(A) selection, and sequenced as 100 bp single-end reads on a
HiSeq2000. We also used previously published RNA-Seq data generated from primary fibroblasts
(isolated from ear clips) from a male (GSM1227965) and female (GSM1227964) African elephant gen-
erated on an Illumina Genome Analyzer IIx (101 cycles, single end) and a male (GSM1278046) African
elephant generated on an Illumina HiSeq 2000 (101 cycles, single end) (Cortez et al., 2014) and
combined these reads into a single dataset of 138,954,285 reads. Finally, we used previously pub-
lished 100 bp single-end reads generated on a HiSeq2000 to identify TP53RTG transcripts from
Asian elephant PBMCs (SRX1423033) (Reddy et al., 2015).
Reads were aligned to a custom built elephant reference gene set generated by combining the
sequences of the canonical TP53 gene and TP53RTG genes with the ENSEMBL African elephant
(Loxodonta africana) CDS gene build (Loxodonta_africana.loxAfr3.75.cds.all.fa) with Bowtie2
(Langmead and Salzberg, 2012). Bowtie two settings were: (1) both local alignment and end-to-
end mapping; (2) preset option: sensitive; (3) Trim n-bases from 5’ of each read: 0; and (4) Trim
n-bases from 3’ of each read: 0. Transcript assembly and FPKM estimates were generated with Cuf-
flinks (version 0.0.7) (Trapnell et al., 2012) using aligned reads from Bowtie2, non-default parame-
ters included quartile normalization and multi-read correction. Finally, we transformed FPKM
estimates into transcripts per million (TPM), TPM=(FPKM per gene/sum FPKM all genes)x106, and
defined genes with TPM  2 as expressed (Li et al., 2010; Wagner et al., 2012, 2013).
The TP53RTG genes are 80.0–82.7% identical to TP53 at the nucleotide level, with 204–231 total
nucleotide differences compared to TP53. This level of divergence allows for many reads to be
uniquely mapped to each gene, there will also be significant read mapping uncertainty in regions of
these genes with few nucleotide differences. However, if read mapping uncertainty was leading to
false positive mappings of TP53 derived reads to TP53RTG genes we would expect to observe
the expression of many TP53RTG genes, rather the robust expression of a single (TP53RTG12) gene.
We also counted the number of uniquely mapped reads to each TP53RTG gene and TP53. We found
that 0–8 reads were uniquely mapped to most TP53RTG genes, except TP53RTG12 which had ~115
uniquely mapped reads across samples and TP53 which had ~3000 uniquely mapped reads across
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tissue samples. Thus we conclude that read mapping uncertainty has not adversely affected our
RNA-Seq analyses.
Gene expression data (PCR and Sanger sequencing)
We further confirmed expression of TP53RTG12 transcripts in elephant cells through RT-PCR, taking
advantage of differences between TP53RTG12 and TP53 sequences to design two aligned primer
sets, one TP53-specific, the other TP53RTG12 specific. TP53RTG12 primers were: 5´ ggg gaa act cct
tcc tga ga 3´ (forward) and 5´ cca gac aga aac gat agg tg 3´ (reverse). TP53 primers were: 5´ atg gga
act cct tcc tga ga 3´ (forward) and 5´ cca gac gga aac cat agg tg 3´ (reverse). The TP53 amplicon is
expected to be 251 bps in length, while deletions present in the TP53RTG12 sequence lead to a
smaller projected amplicon size of 220 bps.
Total RNA was extracted from cultured Loxodonta and Elephas fibroblasts (RNAeasy Plus Mini
kit, Qiagen), then DNase treated (Turbo DNA-free kit, Ambion) and reverse-transcribed using an
olgio-dT primer for cDNA synthesis (Maxima H Minus First Strand cDNA Synthesis kit, Thermo Scien-
tific). Control RT reactions were otherwise processed identically, except for the omission of reverse
transcriptase from the reaction mixture. RT products were PCR-amplified for 45 cycles of 94˚/20 s,
56˚/30 s, 72˚/30 s using a BioRad CFX96 Real Time qPCR detection system and SYBR Green master
mix (QuantiTect, Qiagen). PCR products were electrophoresed on 3% agarose gels for 1 hr at 100
volts, stained with SYBR safe, and imaged in a digital gel box (ChemiDoc MP, BioRad) to visualize
relative amplicon sizes. PCR products were also directly sequenced at the University of Chicago
Genomics core facility, confirming projected product sizes and sequence identities.
Gene prediction, promoter annotation, and TP53RTG transcript
identification
We used geneid v1.2 (http://genome.crg.es/software/geneid/geneid.html) to infer if the TP53RTG12
gene contained a non-coding exon 5’ to the predicted ATG start codon. For gene structure predic-
tion we used the full-length scaffold_825 from African elephant (Broad/loxAfr3) sequence and forced
an internal exon where the TP53RTG12 gene is encoded in scaffold_825. Geneid identified a puta-
tive exon 5’ to the TP53RTG12 gene from nucleotides 1761–1935 and an exon 3’ from nucleotides
6401–6776. We also used GENESCAN (http://genes.mit.edu/cgi-bin/genscanw_py.cgi) to predict
the location of exons in the full-length scaffold_825 sequence and identified a putative exon from
nucleotides 1750–1986. We next used Bowtie2 (Langmead and Salzberg, 2012) to map African and
Asian elephant fibroblast RNA-Seq data onto African elephant scaffold_825 with the default
settings.
Taxonomic distribution of the RTE1_LA retrotransposon
The RTE1_LA non-LTR retrotransposon has previously been described from the African elephant
genome, these elements are generally more than 90% identical to the consensus RTE1_LA sequence
but less than 70% identical to other mammalian RTEs (http://www.girinst.org/2006/vol6/issue3/
RTE1_LA.html). These data suggest that the RTE_LA element has relatively recently expanded in the
elephant genome. To determine the taxonomic distribution of the RTE1_LA element we used BLAT
to search the lesser hedgehog tenrec (Echinops telfairi), rock hyrax (Procavia capensis), West Indian
manatee (Trichechus manatus), armadillo (Dasypus novemcinctus), and sloth (Choloepus hoffmanni)
genomes. We identified numerous copies of the RTE_LA element in the genome of the Afrotherians,
but not the Xenarthran genomes. These data indicate that the RTE_LA element is Afrotherian-spe-
cific, rather than Elephant-specific.
TP53/TP53RTG western blotting
Elephant and Hyrax primary fibroblasts (San Diego Zoo, ’Frozen Zoo’) were grown to confluency in
10 cm dishes at 37˚C/5% CO2 in a culture medium consisting of FGM/EMEM (1:1) supplemented
with insulin, FGF, 6% FBS and Gentamicin/Amphotericin B (FGM-2, singlequots, Clonetics/Lonza).
Culture medium was removed from dishes just prior to UV treatment and returned to cells shortly
afterwards. Experimental cells were exposed to 50 J/m2UV-C radiation in a crosslinker (Stratalinker
2400, Stratagene), while control cells passed through media changes but were not exposed to UV. A
small volume (~3 mL) of PBS covered fibroblasts at the time of UV exposure. To inhibit TP53
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proteolysis, MG-132 (10 mM) was added to experimental cell medium 1 hr prior to UV exposure, and
maintained until the time of cell lysis. 5 hr post-UV treatment, cells were briefly rinsed in PBS, then
lysed and boiled in 2x SDS-PAGE sample buffer. Lysates were separated via SDS-PAGE on 10% gels
for 1 hr at 140 volts, then electrophoretically transferred to PVDF membranes (1 hr at 85 volts).
Membranes were blocked for 1 hr in 5% milk in TBST and incubated overnight at 4˚C with rabbit
polyclonal TP53 antibodies (FL-393, Santa Cruz Biotechnology, and ab131442, Abcam). Blots were
washed 3x in TBST, incubated with HRP-conjugated, anti-rabbit IgG 2˚ antibodies for 1 hr at RT, and
washed four more times in TBST. Protein bands were visualized via enhanced chemiluminescence
(BioRad Clarity), and imaged in a digital gel box (Chemidoc MP, BioRad). Western blots were repli-
cated three independent times.
Co-immunoprecipitation
Human HEK-293 cells were grown to 80% confluency in 20 cm dishes at 37˚C/5% CO2 in a culture
medium consisting of DMEM supplemented with 10% FBS. At 80% confluency, cells were transiently
transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector. After 16 hr the transfec-
tion media was removed and replaced with fresh DMEM, and the cells were incubated an additional
24 hr before harvesting. After removing DMEM and washing cells twice with PBS, 1 mL ice-cold lysis
buffer (20 mM Tris, pH 8.0, 40 mM KCl, 10 mM MgCl2, 10% glycerol, 1% Triton X-100, 1x Complete
EDTA-free protease inhibitor cocktail (Roche), 1x PhosSTOP (Roche)) was added to each plate and
cells were harvested by scraping with a rubber spatula. Cells were then incubated on ice for 30 min
in 420 mM NaCl. The whole cell lysate was cleared by centrifugation at 10,000 rpm for 30 min at
4˚C, and the supernatant was transferred to a clean microfuge tube. After equilibrating protein con-
centrations, 1 mL of sample was mixed with 40 mL of a-MDM2 or a-Myc antibody conjugated aga-
rose beads (Sigma) pre-washed with TNT buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05%
Triton X-100), and rotated overnight at 4˚C. The following day, samples were treated with 50 U
DNase (Roche) and 2.5 mg RNase (Roche) for 60 min at room temperature, as indicated. Samples
were washed 3x with 1 mL wash buffer (150 mM NaCl, 0.5% Triton X-100). After the final wash, aga-
rose beads were resuspended in elution buffer (500 mM Tris pH 7.5, 1 M NaCl), and boiled to elute
immunoprecipitated complexes. Eluted protein was run on Bis-tris gels, probed with antibodies and
visualized by Chemi-luminescence. Serial Westerns were performed for each antibody following
chemical stripping and re-blocking. Antibodies were from Santa Cruz: MDM2 (SMP14) sc-965, lot
#J2314; p53 (Fl-393) sc-6243, lot # D0215; c-Myc (9E10) sc-40, lot # G2413.
ApoTox-Glo viability/cytotoxicity/apoptosis analyses
Primary fibroblasts were grown to 80% confluency in T-75 culture flasks at 37˚C/5% CO2 in a culture
medium consisting of FGM/EMEM (1:1) supplemented with insulin, FGF, 6% FBS and Gentamicin/
Amphotericin B (FGM-2, singlequots, Clonetics/Lonza). 104 cells were seeded into each well of an
opaque bottomed 96-well plate, leaving a column with no cells (background control); each 96-well
plate contained paired elephant and hyrax samples. Serial dilutions of Doxorubicin (0 uM, 0.5 uM,
1.0 uM, 5 uM, 10 uM and 50 uM), Mitomycin c (0 uM, 0.5 uM, 1.0 uM, 5 uM, 10 uM and 50 uM), and
Nutlin-3a (0 uM, 0.5 uM, 1.0 uM, 5 uM, 10 uM and 50 uM) and 90% culture media were added to
each well such that there were four biological replicates for each condition. After 18 hr of incubation
with each drug, cell viability, cytotoxicity, and caspase-3/7 activity were measured using the Apo-
Tox-Glo Triplex Assay (Promega) in a GloMax-Multi+ Reader (Promega). Data were standardized to
no-drug control cells. For UV-C treatment, culture medium was removed from wells prior to UV
treatment and returned to cells shortly afterwards. Experimental cells were exposed to 50 J/m2UV-C
radiation in a crosslinker (Stratalinker 2400, Stratagene), while control cells passed through media
changes but were not exposed to UV. A small volume (~30 uL) of PBS covered fibroblasts at the
time of UV exposure. Cell viability, cytotoxicity, and caspase-3/7 activity were measured using the
ApoTox-Glo Triplex Assay (Promega) in a GloMax-Multi+ Reader (Promega) 6, 12, 28.5 and 54.5 hr
after UV-C treatment. Data were standardized to no UV-C exposure control cells. ApoTox-Glo Tri-
plex Assays were replicated three independent times.
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Luciferase assays
Primary fibroblasts were grown to 80% confluency in T-75 culture flasks at 37˚C/5% CO2 in a culture
medium consisting of FGM/EMEM (1:1) supplemented with insulin, FGF, 6% FBS and Gentamicin/
Amphotericin B (FGM-2, singlequots, Clonetics/Lonza). At confluency, cells were trypsinized, centri-
fuged at 90 g for 10 min and resuspended in nucleofection/supplement solution and incubated for
15 min. After incubation 1ug of the pGL4.38[luc2p/p53 RE/Hygro] luciferase reporter vector and 100
ng of the pGL4.74[hRluc/TK] Renilla reporter vector were transiently transfected into an elephant
and hyrax cells using the Amaxa Basic Nucleofector Kit (Lonza) using protocol T-016. Immediately
following nuleofection, 104 cells were seeded into each well of an opaque bottomed 96-well plate,
leaving a column with no cells (background control); each 96-well plate contained paired elephant
and hyrax samples. 24 hr after nucleofection cells were treated with either vehicle control, Doxorubi-
cin, Mitomycin c, Nutlin-3a, or 50 J/m2UV-C. Luciferase expression was assayed 18 hr after drug/
UV-C treatment cells, using the Dual-Luciferase Reporter Assay System (Promega) in a GloMax-
Multi+ Reader (Promega). For all experiments luciferase expression was standardized to Renilla
expression to control for differences nucleofection efficiency across samples; Luc./Renilla data is
standardized to (Luc./Renilla) expression in untreated control cells. Each luciferase experiment was
replicated three independent times.
siRNA experiments
siRNAs designed to specifically-target TP53RTG were validated via qRT-PCR using the two primer
sets described earlier, which amplify either TP53RTG or canonical TP53 cDNAs, to confirm specificity
and efficacy of knockdown. Sequences of the three TP53RTG-specific siRNAs used are as follows: (1)
5’-CAGCGGAGGCAGUAGAUGAUU-3’, (2) 5’-GGCUCAAGGAAUAUCAGAAUU-3’, (3) 5’-CAG-
CAGCGGAGGCAGUAGAUU-3’ (Dharmacon). Loxodonta fibroblasts were transfected with siRNAs
using Lipofectamine LTX, and tested 48–72 hr later for either TP53 response via luciferase assay or
for cell viability/toxicity/apoptosis via ApoTox-Glo assay.
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